Home > Insider Trading > Filing (0001144204-15-070834)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1006281	Protalix Biotherapeutics Inc.	PLX	Biological Products, (No Disgnostic Substances) (2836)	650643773

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1385115	Yossi Maimon	C/O Protalix Biotherapeutics, Inc. 2 Snunit St, Science Park, Pob 455 Carmiel L3 20100	Vice President & Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-12-14	10,000	$0.78	10,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	185,000	Indirect	By Trust

Footnotes

Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., issued under its 2006 Stock Incentive Plan, as amended June 17, 2012 (the "Plan"). The restricted shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. In addition to the vesting period, vested restricted shares will be subject to a lock-up for a 24-month period commencing upon the vesting date. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control or Corporate Transaction, each as defined in the Plan, and the lock-up periods will terminate.
To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.